Research Use Notice TB-500 + BPC-157 is provided strictly for laboratory research and development purposes
The unique, upstream approach taken by Mardinoglu and team to increase endogenous glutathione synthesis and reduce fatty liver (while supporting methylation balance) based on their work using personalized genome-scale metabolic models, is worth us considering in clinical practice
TPO facilitates the iodination (or organification) of tyrosine residues on thyroglobulin, a precursor protein for thyroid hormones T3 and T4
Tel:0086-25-52078417 Address:No.9 Weidi Road Jiangsu Life-science High-tech Zone, 210046, Nanjing China
FDA, TGA, WADA, and USADA Warnings For searches around thymosin beta-4 FDA TGA WADA USADA warnings , the regulatory picture is consistent across agencies: TB-500 is not an FDA-approved drug, Australia's TGA lists TB-500 among unapproved peptide products with safety, quality, labeling, and import concerns, and WADA/USADA treat thymosin beta-4 derivatives such as TB-500 as prohibited for tested athletes
Two versions exist in research contexts: CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) Half-life of 30 minutes Produces a more natural, brief GHRH signal Preferred when paired with a GHRP for acute pulsatile dosing CJC-1295 with DAC (Drug Affinity Complex) Half-life of 68 days Creates sustained, elevated GH levels rather than pulsatile release Less commonly paired with ipamorelin due to the mismatch in timing For most research protocols pairing with ipamorelin, CJC-1295 without DAC is the standard choice
